Ingrid Pabinger

31.9k total citations · 5 hit papers
541 papers, 20.3k citations indexed

About

Ingrid Pabinger is a scholar working on Hematology, Internal Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ingrid Pabinger has authored 541 papers receiving a total of 20.3k indexed citations (citations by other indexed papers that have themselves been cited), including 336 papers in Hematology, 207 papers in Internal Medicine and 123 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ingrid Pabinger's work include Venous Thromboembolism Diagnosis and Management (207 papers), Blood Coagulation and Thrombosis Mechanisms (168 papers) and Platelet Disorders and Treatments (125 papers). Ingrid Pabinger is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (207 papers), Blood Coagulation and Thrombosis Mechanisms (168 papers) and Platelet Disorders and Treatments (125 papers). Ingrid Pabinger collaborates with scholars based in Austria, United States and Germany. Ingrid Pabinger's co-authors include Cihan Ay, Christoph Zielinski, Peter Quehenberger, Klaus Lechner, J. Thaler, Rainer Vormittag, Daniela Dunkler, Florian Posch, Christine Mannhalter and Paul A. Kyrle and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Ingrid Pabinger

515 papers receiving 19.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prediction of venous thromboembolism in cancer patients

2010 570 citations Cihan Ay, Christine Marosi et al. Blood profile →
Cancer-associated venous thromboembolism: Burden, mechanisms, and management

2016 337 citations Cihan Ay, Ingrid Pabinger et al. profile →
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

2016 249 citations Ingrid Pabinger et al. profile →
Cancer-associated venous thromboembolism

2022 235 citations Ingrid Pabinger, Florian Moik et al. profile →
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

2018 230 citations Ingrid Pabinger, Nick van Es et al. profile →

Peers

Countries citing papers authored by Ingrid Pabinger

Since Specialization

Citations

This map shows the geographic impact of Ingrid Pabinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Pabinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Pabinger more than expected).

Fields of papers citing papers by Ingrid Pabinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Pabinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Pabinger. The network helps show where Ingrid Pabinger may publish in the future.

Co-authorship network of co-authors of Ingrid Pabinger

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Pabinger. A scholar is included among the top collaborators of Ingrid Pabinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Pabinger. Ingrid Pabinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study 2025 ·EClinicalMedicine ·Florian Moik, Erzsébet Horváth–Puhó, Cihan Ay, Ingrid Pabinger, Frits I. Mulder, Nick van Es, Henrik Toft Sørensen	0
2	Anxiety in patients with venous thromboembolism: quantification and risk factors in a prospective cohort study 2024 ·Journal of Thrombosis and Haemostasis ·Daniel Steiner, Stephan Nopp, (unknown), Ingrid Pabinger, Benedikt Weber, Cihan Ay	6
3	Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia 2024 ·Gene Therapy ·Ingrid Pabinger, (unknown), Miguel A. Escobar, Barbara A. Konkle, María Eva Mingot‐Castellano, Eric S. Mullins, Claude Négrier, Luying Pan, (unknown), Brian Yan, John Chapin	9
4	Women with severe postpartum hemorrhage have a decreased endogenous thrombin potential before delivery 2023 ·Journal of Thrombosis and Haemostasis ·Claire de Moreuil, Yesim Dargaud, Christophe Nougier, Pierre‐François Dupré, (unknown), (unknown), (unknown), (unknown), Ingrid Pabinger, Cihan Ay, Françis Couturaud, Brigitte Pan‐Petesch	3
5	Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange: Analysis of Efficacy and Safety Data 2023 ·Blood ·Lucas Kühne, Paul Knoebl, Kathrin Eller, Ingrid Pabinger, Paul T. Brinkkoetter, (unknown)	1
6	Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study 2023 ·Journal of Thrombosis and Haemostasis ·Stephan Nopp, Florian Moik, Simon Kraler, (unknown), Matthias Preusser, Arnold von Eckardstein, Ingrid Pabinger, Thomas F. Lüscher, Cihan Ay	4
7	Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland 2023 ·Oncology Research and Treatment ·Axel Matzdorff, Sonja Alesci, Johanna Gebhart, Susanne Holzhauer, Marie Luise Hütter‐Krönke, Thomas Kühne, Oliver Meyer, Helmut Ostermann, Ingrid Pabinger, Mathias Rummel, Ulrich J. Sachs, (unknown), Karolin Trautmann‐Grill, Bernhard Wörmann	13
8	Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation 2023 ·International Journal of Molecular Sciences ·Stephan Nopp, M. Leontien van der Bent, (unknown), Oliver Königsbrügge, Johann Wojta, Ingrid Pabinger, Cihan Ay, A. Yaël Nossent	4
9	Expertenreport Immunthrombozytopenie – Aktuelle Diagnostik und Therapie 2022 ·Oncology Research and Treatment ·Axel Matzdorff, Sonja Alesci, Johanna Gebhart, Susanne Holzhauer, Marie Luise Hütter‐Krönke, Thomas Kühne, Oliver Meyer, Helmut Ostermann, Ingrid Pabinger, Mathias Rummel, Ulrich J. Sachs, (unknown), Karolin Trautmann‐Grill, Bernhard Wörmann	0
10	Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting 2022 ·Research and Practice in Thrombosis and Haemostasis ·(unknown), (unknown), Michiel Coppens, Samantha C. Gouw, Sara Boyce, Catherine Bagot, Erik A.M. Beckers, Paul Brons, Giancarlo Castaman, Jeroen Eikenboom, Shannon Jackson, Marieke J. H. A. Kruip, Frank W.G. Leebeek, Karina Meijer, Laurens Nieuwenhuizen, Ingrid Pabinger, Karin Fijnvandraat	7
11	Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII 2022 ·Journal of Thrombosis and Haemostasis ·Yong Hu, Andreas Repa, Ton Lisman, Gülen Yerlikaya‐Schatten, Chi M. Hau, Ingrid Pabinger, Cihan Ay, Rienk Nieuwland, J. Thaler	13
12	Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis 2021 ·European Heart Journal ·Ella Grilz, Florian Posch, Stephan Nopp, Oliver Königsbrügge, Iréne Lang, Peter Klimek, Stefan Thurner, Ingrid Pabinger, Cihan Ay	83
13	Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency 2021 ·Blood Advances ·(unknown), Alexander Tolios, Stefanie Hofer, Cihan Ay, Helmuth Haslacher, (unknown), Willem H. Ouwehand, Kate Downes, Matthias Haimel, Ingrid Pabinger, Johanna Gebhart	20
14	Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study 2021 ·Haemophilia ·Mark T. Reding, Ingrid Pabinger, Pål André Holme, Lone Hvitfeldt Poulsen, Claude Négrier, Pavani Chalasani, Monika Maas Enriquez, Maria Wang, Karina Meijer, Maria Elisa Mancuso, Shadan Lalezari	15
15	Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis 2020 ·Research and Practice in Thrombosis and Haemostasis ·Stephan Nopp, Florian Moik, Bernd Jilma, Ingrid Pabinger, Cihan Ay	286
16	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer 2019 ·British Journal of Haematology ·Ella Grilz, Lisa‐Marie Mauracher, Florian Posch, Oliver Königsbrügge, Sabine Zöchbauer‐Müller, Christine Marosi, Iréne Lang, Ingrid Pabinger, Cihan Ay	99
17	Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial 2016 ·Blood ·Elena Santagostino, U. Martinowitz, Toshko Lissitchkov, Brigitte Pan‐Petesch, Hideji Hanabusa, Johannes Oldenburg, Lisa Boggio, Claude Négrier, Ingrid Pabinger, M. von Depka Prondzinski, Carmen Altisent, Giancarlo Castaman, Koji Yamamoto, (unknown), C. Voigt, Nicole Blackman, Iris Jacobs	150
18	Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS) 2015 ·Clinical Cancer Research ·Florian Posch, J. Thaler, Gerhard J. Zlabinger, Oliver Königsbrügge, Silvia Koder, Christoph Zielinski, Ingrid Pabinger, Cihan Ay	40
19	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease 2011 ·European Journal of Clinical Investigation ·(unknown), (unknown), Cihan Ay, (unknown), Silvia Koder, G. Schernthaner, Ingrid Pabinger, Guntram Schernthaner	23
20	FACTOR-V LEIDEN AS AN INDEPENDENT RISK FACTOR FOR THROMBOSIS IN ANTITHROMBIN DEFICIENCY TYPE-II - HEPARIN-BINDING SITE 1995 ·UCL Discovery (University College London) ·(unknown), (unknown), Badrul Chowdhury, (unknown), J Conard, Ingrid Pabinger, David A. Lane	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact